--- title: "ICON Restructures Debt and Divests Symphony Ahead of Note Maturities" type: "News" locale: "en" url: "https://longbridge.com/en/news/294376596.md" description: "ICON (ICLR) repaid $500M maturing notes using a new bridge facility and divested Symphony Health Solutions to HealthVerity, booking a $32.9M loss. These moves aim to extend debt maturity and align assets with core strategies. Analysts rate ICLR as Buy with an $185 target, citing financial resilience despite margin compression." datetime: "2026-07-30T13:28:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294376596.md) - [en](https://longbridge.com/en/news/294376596.md) - [zh-HK](https://longbridge.com/zh-HK/news/294376596.md) generator: "portal-rs" --- # ICON Restructures Debt and Divests Symphony Ahead of Note Maturities An update from Icon ( (ICLR) ) is now available. On July 15, 2026, ICON drew down a new $500 million Bridge Secured Credit Facility arranged in April and used the proceeds to fully repay its $500 million 2.875% Senior Secured Notes that matured the same day. The bridge loan, which runs to April 26, 2027, extends the group’s debt maturity profile and underscores ongoing access to secured funding backed by extensive subsidiary guarantees and collateral. On May 8, 2026, ICON completed the disposal of Symphony Health Solutions to HealthVerity via a merger, receiving HealthVerity stock as consideration and simultaneously investing an additional $37.5 million for a minority stake. ICON booked a $32.9 million loss on the sale and, by June 30, 2026, had written the carrying value of its HealthVerity investment to nil, signaling a strategic exit from Symphony’s operations while retaining limited exposure to HealthVerity’s data business. The company’s recent capital structure moves, combined with its broad international footprint and multi-currency revenue and cost base, highlight both financial flexibility and exposure to foreign exchange swings. For stakeholders, the refinancing of maturing notes and the sale of Symphony mark continued portfolio reshaping and balance sheet management as ICON seeks to align its assets and funding with its core clinical research and healthcare intelligence strategy. The most recent analyst rating on (ICLR) stock is a Buy with a $185.00 price target. To see the full list of analyst forecasts on Icon stock, see the ICLR Stock Forecast page. **Spark’s Take on ICLR Stock** According to Spark, TipRanks’ AI Analyst, ICLR is a Outperform. ICLR’s score reflects solid underlying financial resilience (improving leverage and strong absolute cash generation) and strong current technical momentum (price above key moving averages with positive MACD). These positives are tempered by valuation (P/E ~30) and business fundamentals highlighted on the earnings call—strong bookings and maintained guidance, but meaningful year-over-year margin compression and muted revenue growth. To see Spark’s full report on ICLR stock, click here. **More about Icon** ICON plc is a global contract research organization that provides outsourced clinical development services to pharmaceutical, biotechnology, medical device, and government and public health clients. The Ireland-based group runs trials from compound selection through Phase I–IV studies and operates with about 40,200 employees across 99 locations in 55 countries, with revenue largely generated in the U.S. and Europe. Founded in 1990, ICON has expanded through organic growth and strategic acquisitions to deepen its capabilities across major therapeutic areas and clinical functions. The company positions itself as a healthcare intelligence partner, offering stand-alone, full-service, and blended-service solutions that support sponsors’ increasingly complex global development programs and regulatory requirements. ICON’s geographic reach and multi-currency operations expose it to foreign exchange volatility, as it reports in U.S. dollars while earning revenue and incurring expenses in currencies such as the euro and pound sterling. This currency mix, combined with contracts and costs denominated across markets, can affect reported financial results and adds a layer of financial management complexity for investors and stakeholders. **Average Trading Volume:** 1,011,930 **Technical Sentiment Signal:** Buy **Current Market Cap:** $13.8B ### Related Stocks - [ICLR.US](https://longbridge.com/en/quote/ICLR.US.md) ## Related News & Research - [ICON plc Raises $2.15 Billion in Senior Notes to Refinance Secured Debt](https://longbridge.com/en/news/296253678.md) - [ICON announces availability of ICON Cares 2025 ESG report](https://longbridge.com/en/news/296491257.md) - [ICON sells USD 2.15 billion senior unsecured notes in three-part offering](https://longbridge.com/en/news/296236277.md) - [Director Of Icon Makes $138K Sale](https://longbridge.com/en/news/295817871.md) - [ICON (ICLR) Could Be 13% Overvalued On Q1 Earnings And Repeated Outlook](https://longbridge.com/en/news/291799926.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**